ScripIn the past few months, South Korean bioventures, including ABL Bio , have clinched a series of large-scale global out-licensing deals, dominating the transactions in the country so far this year. So
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
ScripDisappointing news appeared to overflow in the South Korean biotech sector in the second quarter amid multiple returned assets from global partners, a lack of major new out-licensing deals, as well as
ScripFibroGen, Inc. ’s monoclonal antibody candidate pamrevlumab has disappointed in the Phase III ZEPHYRUS-1 trial in idiopathic pulmonary fibrosis (IPF), rendering the drug’s future prospects even more u